厄贝沙坦对中老年男性高血压病患者骨质代谢的影响

Effect of irbesartan on skeletal metabolism in moderately elderly males with primary hypertension

目的探讨厄贝沙坦对中老年男性原发性高血压(primary hypertension,PH)患者骨质代谢的影响。方法回顾性分析,随机选择年龄在40~89岁的中老年男性PH患者94例。按服用治疗高血压药物的类别分为2组:厄贝沙坦治疗组(34例,长期服用治疗剂量厄贝沙坦)和对照组[60例,服用非血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)类药物]。分别比较2组血清钙、磷浓度、碱性磷酸酶(alkaline phosphatase,ALP)浓度、骨密度(bone mineral density,BMD)、骨折发生率的差异。结果厄贝沙坦治疗组患者股骨颈部、股骨总和、腰椎部位BMD和BMD与正常成人峰值比较积分(T值)相较于非ACEI/ARB类药物治疗组显著增加。结论厄贝沙坦对于中老年男性PH患者具有一定的骨保护作用。

AIM To observe the effect of irbesartan on skeletal metabolism in moderately elderly males with primary hypertension （PH）. METHODS Ninety-four male PH patients aged from 40 -89 years were enrolled and divided into irbesartan group （therapeutic dose, 〉 3 years, n = 34） and contral no treatment group （no ACEI/ARB treatment, n = 60）. The difference of bone mineral density （BMD）, fracture ratio, concentration of serum calcium, phosphorus and alkaline phosphatase was compared between groups. RESULTS Compared with those in the no ACEI/ARB treatment group, T value and BMD of femoral neck, total femur and vertebra lumbalis increased significantly in irbesartan group. CONCLUSION Irbesartan exerts protective effects on the skeletal system in moderately elderly males with PH.